Ampalex

Ampakine and nootropic CAS# 154235-83-3

Ampalex

Catalog No. BCC1359----Order now to get a substantial discount!

Product Name & Size Price Stock
Ampalex: 5mg $12 In Stock
Ampalex: 10mg Please Inquire In Stock
Ampalex: 20mg Please Inquire Please Inquire
Ampalex: 50mg Please Inquire Please Inquire
Ampalex: 100mg Please Inquire Please Inquire
Ampalex: 200mg Please Inquire Please Inquire
Ampalex: 500mg Please Inquire Please Inquire
Ampalex: 1000mg Please Inquire Please Inquire
Related Products
  • Tezampanel

    Catalog No.:BCC1993
    CAS No.:154652-83-2
  • Noopept

    Catalog No.:BCC1804
    CAS No.:157115-85-0
  • LY450108

    Catalog No.:BCC1725
    CAS No.:376594-67-1
  • Perampanel

    Catalog No.:BCC1847
    CAS No.:380917-97-5
  • Aniracetam

    Catalog No.:BCC4219
    CAS No.:72432-10-1

Quality Control of Ampalex

Number of papers citing our products

Chemical structure

Ampalex

3D structure

Chemical Properties of Ampalex

Cas No. 154235-83-3 SDF Download SDF
PubChem ID 148184 Appearance Powder
Formula C14H15N3O M.Wt 241.29
Type of Compound N/A Storage Desiccate at -20°C
Synonyms CX516; BDP 12; Ampakine CX516
Solubility DMSO : ≥ 41 mg/mL (169.92 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name piperidin-1-yl(quinoxalin-6-yl)methanone
SMILES C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2
Standard InChIKey ANDGGVOPIJEHOF-UHFFFAOYSA-N
Standard InChI InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Ampalex

DescriptionAmpalex (Ampakine CX516; CX516; BDP 12) is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator as a treatment for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI). IC50 value: Target: AMPA receptor Ampalex ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Researches suggest that AMPA receptors may be potential pharmaceutical targets for the treatment of neurodegenerative diseases, and highlights AMPAkines, in particular, as possible therapeutic agents.

References:
[1]. Broberg BV, Glenth?j BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl). 2009 [2]. Kanju PM, Parameshwaran K, Sims C, et al. Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Exp Neurol. 2008 Nov;214(1):55-61. [3]. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb;33(3):465-72. [4]. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets. 2007 May;8(5):603-20. [5]. Johnson SA, Simmon VF. Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. J Mol Neurosci. 2002 Aug-Oct;19(1-2):197-200.

Ampalex Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Ampalex Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Ampalex

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.1444 mL 20.722 mL 41.4439 mL 82.8878 mL 103.6098 mL
5 mM 0.8289 mL 4.1444 mL 8.2888 mL 16.5776 mL 20.722 mL
10 mM 0.4144 mL 2.0722 mL 4.1444 mL 8.2888 mL 10.361 mL
50 mM 0.0829 mL 0.4144 mL 0.8289 mL 1.6578 mL 2.0722 mL
100 mM 0.0414 mL 0.2072 mL 0.4144 mL 0.8289 mL 1.0361 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Ampalex

Ampalex (Ampakine CX516) is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator as a treatment for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI). Ampalex ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. Researches suggest that AMPA receptors may be potential pharmaceutical targets for the treatment of neurodegenerative diseases, and highlights AMPAkines, in particular, as possible therapeutic agents.

Featured Products
New Products
 

References on Ampalex

Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model.[Pubmed:11959085]

Eur J Pharmacol. 2002 Apr 5;440(1):27-35.

The present study tests the activity of nootropic drugs in a behavioral test linked to depression. This test measures the reduction of submissive behavior in a competition test as the relative success of two food-restricted rats to gain access to a feeder. Nootropic drugs tested include piracetam (2-oxo-1-pyrrolidineacetamide), aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone), the Ampakine, Ampalex, 1-(quinoxalin-6-ylcarbonyl)piperidine, and analogs were compared to the antidepressants, fluoxetine ((+/-)-N-methyl-gamma-(4-[trifluoromethyl]phenoxy)-benzenepropanamine) and desimpramine (5H-dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride), while the anxiolytic diazepam (7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one) served as a control. Drugs were given intraperitoneally for 3 weeks. The antidepressant and nootropic drugs reduced submissive behavior over time. The effect was dose dependent as measured for fluoxetine and Ampakines. The reduction of submissive behavior by Ampakines gradually faded after cessation of treatment and had a more rapid onset of activity (during the 1st week of treatment) than fluoxetine (after 2 weeks). The results suggest that Ampakines may have antidepressant activity. The potential of depression treatment with memory-enhancing drugs is hypothesized and the link between cognition and depression is discussed.

Description

Ampalex (Ampakine CX516; CX516; BDP 12) is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator as a treatment for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).

Keywords:

Ampalex,154235-83-3,CX516; BDP 12; Ampakine CX516,Natural Products,AMPAR, buy Ampalex , Ampalex supplier , purchase Ampalex , Ampalex cost , Ampalex manufacturer , order Ampalex , high purity Ampalex

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: